Creso Pharma (ASX:CPH) is a global medicinal cannabis innovator that develops cannabis and hemp-derived therapeutic, nutraceutical and lifestyle products for both people and animals. Founded by a team of highly experienced pharmaceutical executives, Creso set out to leverage cutting edge science and research to develop, register and commercialise innovative cannabis and hemp derived products.
It was the first company to import medical cannabis to Australia and it has a presence across Canada, under its subsidiary Mernova, Switzerland and the EU, Israel, Latin America and Australia.
Dr Miri Halperin Wernli, Group CEO, Co-Founder and Executive Director
Dr Miri Halperin Wernli has over 25 years of strategic and operational leadership in global drug and product development in the pharmaceutical and biomedical industries. She held worldwide executive leadership positions in R&D and in strategic marketing within global pharmaceutical companies in Switzerland and in the US.
Boaz Wachtel, Non-Executive Chairman and Co-Founder
Boaz Wachtel is a leading medical cannabis expert, co-founder and former managing director of Phytotech Medical (MMJ.ASX), Australia’s first publicly traded medical cannabis company. He initiated and helped implement the National Medical Cannabis Program in Israel.
John Griese, Chief Operating Officer
John Griese is an expert in cannabis and food manufacturing and supply chain. John has 30 years experience in executive operations roles with Pepsi and Nestle and more recently developed Cannabis experience as COO of Bloom Farms a large branded manufacturer and distributor in the California regulated market.